{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:18:27Z","timestamp":1787822307975,"version":"build-2784847793"},"reference-count":40,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR21\/00041"],"award-info":[{"award-number":["JR21\/00041"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/01468"],"award-info":[{"award-number":["PI23\/01468"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB16\/11\/00420"],"award-info":[{"award-number":["CB16\/11\/00420"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB16\/11\/00486"],"award-info":[{"award-number":["CB16\/11\/00486"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"award":["JR21\/00041"],"award-info":[{"award-number":["JR21\/00041"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}]},{"award":["PI23\/01468"],"award-info":[{"award-number":["PI23\/01468"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}]},{"award":["CB16\/11\/00420"],"award-info":[{"award-number":["CB16\/11\/00420"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}]},{"award":["CB16\/11\/00486"],"award-info":[{"award-number":["CB16\/11\/00486"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Respiratory syncytial virus (RSV) causes morbidity in older adults with cardiovascular disease, in whom infection may precipitate severe lower respiratory tract disease, hospitalization, functional decline, and cardiovascular destabilization. We evaluate the evidence for RSV vaccination in cardiovascular disease and propose a jurisdiction-adaptable framework for integrating vaccination into cardiovascular care. Methods: Observational studies, randomized trials, pragmatic and test-negative studies, prespecified cardiovascular analyses of DAN-RSV, and eligibility recommendations were narratively synthesized and translated into a pathway encompassing patient identification, eligibility and risk assessment, vaccine delivery and co-administration, documentation, and follow-up. Results: Acute cardiac events are frequent during RSV hospitalization, and cardiovascular risk may persist after infection. Randomized trials establish protection against RSV-associated lower respiratory tract disease and respiratory illness, while real-world studies support effectiveness against RSV-related hospitalization. DAN-RSV reduced all-cause cardiorespiratory hospitalization but did not demonstrate significant reductions in cardiovascular hospitalization, myocardial infarction, heart failure (HF) hospitalization, atrial fibrillation, stroke, cardiovascular death, or major adverse cardiovascular events; observational associations with lower post-vaccination cardiovascular-event rates remain hypothesis-generating. The framework prioritizes adults aged \u226575 years and those aged 50\u201374 years with high-risk cardiovascular conditions where consistent with national recommendations, embeds vaccination assessment across cardiology, HF, primary care, pharmacy, and long-term care, and incorporates co-administration, documentation, and outcome surveillance. Conclusions: The principal contribution is a pathway for moving RSV vaccination from recommendation to routine preventive care for adults with cardiovascular disease. It anchors implementation in established RSV and cardiorespiratory benefits while treating cardiovascular-event reduction as a research priority rather than a demonstrated indication.<\/jats:p>","DOI":"10.3390\/jcm15176602","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:04:32Z","timestamp":1787756672000},"page":"6602","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Respiratory Syncytial Virus Vaccination as Cardiopulmonary and Cardiovascular Risk Mitigation in Adults with Heart Disease"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8665-7107","authenticated-orcid":false,"given":"Clara","family":"Bonanad","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Valencia, 46010 Valencia, Spain"},{"name":"Fundaci\u00f3n Para la Investigaci\u00f3n del Hospital Cl\u00ednico de la Comunidad Valenciana (INCLIVA), 46010 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario de Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6135-7685","authenticated-orcid":false,"given":"Vivencio","family":"Barrios","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Ram\u00f3n y Cajal, Universidad de Alcal\u00e1, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0303-4110","authenticated-orcid":false,"given":"Guillermo","family":"Barreres","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Para la Investigaci\u00f3n del Hospital Cl\u00ednico de la Comunidad Valenciana (INCLIVA), 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Garcia-Collado","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Para la Investigaci\u00f3n del Hospital Cl\u00ednico de la Comunidad Valenciana (INCLIVA), 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3496-791X","authenticated-orcid":false,"given":"Daniela","family":"Maidana","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Hospital Universitario Virgen Macarena, 41042 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vivas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico San Carlos, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Raposeiras","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario \u00c1lvaro Cunqueiro, 38312 Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fortuny","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Son Espases, 07120 Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Segura-Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Cl\u00ednico San Cecilio, 18016 Granada, Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria ibs.GRANADA, 18012 Granada, Spain"},{"name":"Department of Medicine, University of Granada, 18071 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5914-8526","authenticated-orcid":false,"given":"Gonzalo","family":"Alonso-Salinas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Navarra, 31008 Pamplona, Spain"},{"name":"Departamento de Ciencias de la Salud, Universidad P\u00fablica de Navarra (UPNA), 31006 Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-979X","authenticated-orcid":false,"given":"Esther","family":"Redondo","sequence":"additional","affiliation":[{"name":"Technical Unit for Vaccination and International Health, Madrid Salud Autonomous Organization, 28007 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8986-2584","authenticated-orcid":false,"given":"Alberto","family":"Garcia-Lled\u00f3","sequence":"additional","affiliation":[{"name":"Departamento de Cardiolog\u00eda, Hospital Universitario Pr\u00edncipe de Asturias, 28805 Alcala de Henares, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1998-3735","authenticated-orcid":false,"given":"Sergio","family":"Garc\u00eda-Blas","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Para la Investigaci\u00f3n del Hospital Cl\u00ednico de la Comunidad Valenciana (INCLIVA), 46010 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario de Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jacc.2018.02.013","article-title":"Respiratory Syncytial Virus and Associations with Cardiovascular Disease in Adults","volume":"71","author":"Ivey","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jamainternmed.2024.0212","article-title":"Acute Cardiac Events in Hospitalized Older Adults with Respiratory Syncytial Virus Infection","volume":"184","author":"Woodruff","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2547618","DOI":"10.1001\/jamanetworkopen.2025.47618","article-title":"Cardiovascular Events 1 Year After Respiratory Syncytial Virus Infection in Adults","volume":"8","author":"Hviid","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.jacc.2025.02.031","article-title":"Respiratory Syncytial Virus and Incidence of Cardiovascular Events: A Nationwide Self-Controlled Case Series Analysis","volume":"85","author":"Lassen","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kujawski, S.A., Whitaker, M., Ritchey, M.D., Reingold, A.L., Chai, S.J., Anderson, E.J., Openo, K.P., Monroe, M., Ryan, P., and Bye, E. (2022). Rates of respiratory syncytial virus (RSV)-associated hospitalization among adults with congestive heart failure\u2014United States, 2015\u20132017. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264890"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/ciy991","article-title":"Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults","volume":"69","author":"Ackerson","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e13031","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults","volume":"388","author":"Papi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S2213-2600(25)00048-7","article-title":"Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): A multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"13","author":"Ison","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMc2311560","article-title":"RENOIR Trial\u2014RSVpreF Vaccine Efficacy over Two Seasons","volume":"391","author":"Walsh","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_13","first-page":"CD016131","article-title":"Efficacy and safety of respiratory syncytial virus vaccines","volume":"9","author":"King","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of Respiratory Syncytial Virus Vaccines in Adults Aged 60 Years and Older: Updated Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_15","unstructured":"Centers for Disease Control and Prevention (2026, June 26). RSV Vaccine Guidance for Adults. Updated 24 February 2026, Available online: https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/adults.html."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2509810","article-title":"RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults","volume":"394","author":"Lassen","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jama.2025.15405","article-title":"Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Randomized Clinical Trial","volume":"334","author":"Lassen","year":"2025","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1001\/jama.2025.15896","article-title":"RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons","volume":"334","author":"Surie","year":"2025","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1093\/eurheartj\/ehaf679","article-title":"Effectiveness of bivalent respiratory syncytial virus prefusion F vaccine in individuals with or without atherosclerotic cardiovascular disease: A prespecified secondary analysis of the DAN-RSV trial","volume":"46","author":"Pareek","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41579-023-00919-w","article-title":"Respiratory syncytial virus infection and novel interventions","volume":"21","author":"Langedijk","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S2213-2600(24)00255-8","article-title":"Respiratory syncytial virus infections in adults: A narrative review","volume":"12","author":"Wildenbeest","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/eurjpc\/zwae016","article-title":"Association of respiratory infections and the impact of vaccinations on cardiovascular diseases","volume":"31","author":"Rademacher","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/cid\/ciab595","article-title":"Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017\u20132020","volume":"74","author":"Branche","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"ofag341","DOI":"10.1093\/ofid\/ofag341","article-title":"Hospitalization Burden Estimates of Respiratory Syncytial Virus with Adjustment for Case Underascertainment in Adults Aged 18 to 65 Years in High-Income Countries: A Systematic Review, Meta-Analysis, and Modeling Study","volume":"13","author":"Li","year":"2026","journal-title":"Open Forum Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2556767","DOI":"10.1001\/jamanetworkopen.2025.56767","article-title":"Risk of Cardiorespiratory Events Following Respiratory Syncytial Virus-Related Hospitalization","volume":"9","author":"Liang","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1093\/cid\/ciaf310","article-title":"Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized with Respiratory Syncytial Virus","volume":"82","author":"Sudnik","year":"2026","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"250160","DOI":"10.1183\/16000617.0160-2025","article-title":"The risk of cardiac disease events after respiratory syncytial virus disease: A systematic literature review and meta-analysis","volume":"35","author":"Montiel","year":"2026","journal-title":"Eur. Respir. Rev."},{"key":"ref_28","first-page":"31","article-title":"Percepci\u00f3n de los profesionales sanitarios de la vacunaci\u00f3n del paciente cardi\u00f3pata adulto desde la Cardiolog\u00eda","volume":"21","author":"Bonanad","year":"2026","journal-title":"Latido"},{"key":"ref_29","unstructured":"US Food and Drug Administration (2026, July 02). MRESVIA (Respiratory Syncytial Virus Vaccine) Prescribing Information and Regulatory Review Materials, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/mresvia."},{"key":"ref_30","unstructured":"European Medicines Agency (2026, August 17). mResvia: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mresvia-epar-product-information_en.pdf."},{"key":"ref_31","unstructured":"UK Health Security Agency (2026, August 17). RSV Vaccination of Older Adults: Information for Healthcare Practitioners, Available online: https:\/\/www.gov.uk\/government\/publications\/respiratory-syncytial-virus-rsv-programme-information-for-healthcare-professionals\/rsv-vaccination-of-older-adults-information-for-healthcare-practioners."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/cid\/ciad707","article-title":"Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Older Adults","volume":"78","author":"Athan","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/cid\/ciae365","article-title":"Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine When Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial","volume":"79","author":"Clark","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(24)00589-9","article-title":"Safety and Immunogenicity of mRNA-1345 RSV Vaccine Coadministered with an Influenza or COVID-19 Vaccine in Adults Aged 50 Years or Older: An Observer-Blinded, Placebo-Controlled, Randomised, Phase 3 Trial","volume":"25","author":"Goswami","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Neutel, J.M., Erdem, R., Jiang, Q., Cannon, K., Stacey, H., Newton, R., Gomme, E.A., Li, W., Mensa, F.J., and T\u00fcreci, \u00d6. (2025). Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or without Quadrivalent Influenza Vaccine in Adults \u226565 Years of Age. Vaccines, 13.","DOI":"10.3390\/vaccines13020158"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Singer, D., Steffens, A., La, E.M., Buikema, A.R., Horn, E.K., Theiss-Nyland, K., Fonseca, M.J., Gerber, S.I., Kawai, A., and Johnson, M.G. (2026). Effectiveness of the Adjuvanted Respiratory Syncytial Virus Prefusion F3 Vaccine in Preventing Major Adverse Cardiovascular Events and Severe Exacerbations of COPD and Asthma Among US Adults \u2265 60 Years of Age. Chest, S0012-3692(26)06182-9.","DOI":"10.1016\/j.chest.2026.06.059"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1093\/eurheartj\/ehaf384","article-title":"Vaccination as a new form of cardiovascular prevention: A European Society of Cardiology clinical consensus statement","volume":"46","author":"Heidecker","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.jacc.2025.07.003","article-title":"2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Adult Immunizations as Part of Cardiovascular Care","volume":"86","author":"Heidenreich","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","unstructured":"US Food and Drug Administration (2026, July 02). Adult Respiratory Syncytial Virus Vaccine Prescribing and Approval Information, Including Product-Specific Labels for FDA-Licensed Adult RSV Vaccines, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states."},{"key":"ref_40","unstructured":"European Medicines Agency (2026, June 26). Arexvy: European Public Assessment Report and Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arexvy."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6602\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:24:56Z","timestamp":1787819096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":40,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176602"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176602","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}